Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Transfusion ; 62(11): 2235-2244, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36129204

RESUMEN

BACKGROUND: Perioperative bleeding and transfusion have been associated with adverse outcomes after cardiac surgery. The use of factor eight inhibiting bypass activity (FEIBA) in managing bleeding after repair of acute Stanford type A aortic dissection (ATAAD) has not previously been evaluated. We report our experience in utilizing FEIBA in ATAAD repair. STUDY DESIGN AND METHODS: A retrospective review was undertaken of all consecutive patients who underwent repair of ATAAD between July 2014 and December 2019. Patients were divided into two groups, dependent upon whether or not they received FEIBA intraoperatively: "FEIBA" (n = 112) versus "no FEIBA" (n = 119). From this, 53 propensity-matched pairs of patients were analyzed with respect to transfusion requirements and short-term clinical outcomes. RESULTS: Thirty-day mortality for the entire cohort was 11.7% (27 deaths), not significantly different between patient groups. Those patients who received FEIBA demonstrated reduced transfusion requirements for all types of blood products in the first 48 h after surgery as compared with the "no FEIBA" cases, including red blood cells, platelets, plasma, and cryoprecipitate (p < .0001). There was no significant difference in major postoperative morbidity between the two groups. The FEIBA cohort did not demonstrate an increased incidence of thrombotic complications (stroke, deep venous thrombosis, pulmonary thromboembolism). DISCUSSION: When used as rescue therapy for refractory bleeding following repair of ATAAD, FEIBA appears to be effective in decreasing postoperative transfusion requirements whilst not negatively impacting clinical outcomes. These findings should prompt further investigation and validation via larger, multi-center, randomized trials.


Asunto(s)
Disección Aórtica , Procedimientos Quirúrgicos Cardíacos , Humanos , Factor VIII/uso terapéutico , Factores de Coagulación Sanguínea/uso terapéutico , Disección Aórtica/cirugía , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Hemorragia Posoperatoria/etiología , Estudios Retrospectivos , Resultado del Tratamiento
2.
J Support Oncol ; 11(2): 95-102, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23967496

RESUMEN

BACKGROUND: Burnout among physicians can lead to decreased career satisfaction, physical and emotional exhaustion, and increased medical errors. In oncologists, high exposure to fatal illness is associated with burnout. METHODS: The Maslach Burnout Inventory, measuring Emotional Exhaustion (EE), Depersonalization (DP), and Personal Accomplishment (PA), was administered to second-year US oncology fellows. Bivariate and multivariate analyses explored associations between burnout and fellow demographics, attitudes, and educational experiences. RESULTS: A total of 254 fellows out of 402 eligible US fellows responded (63.2%) and 24.2% reported high EE, 30.0% reported high DP, and 26.8% reported low PA. Over half of the fellows reported burnout in at least one domain. Lower EE scores were associated with the fellows' perceptions of having received better teaching, explicit teaching about certain end-of-life topics, and receipt of direct observation of goals-of-care discussions. Fellows who reported better overall teaching quality and more frequent observation of their skills had less depersonalization. Fellows who felt a responsibility to help patients at the end of life to prepare for death had higher PA. LIMITATIONS: This survey relies on the fellows' self-reported perceptions without an objective measure for validation. Factors associated with burnout may not be causal. The number of analyses performed raises the concern for Type I errors; therefore, a stringent P value (0.01) was used. CONCLUSIONS: Burnout is prevalent during oncology training. Higher-quality teaching is associated with less burnout among fellows. Fellowship programs should recognize the prevalence of burnout among oncology fellows as well as components of training that may protect against burnout.


Asunto(s)
Agotamiento Profesional/epidemiología , Oncología Médica/educación , Cuidados Paliativos , Adulto , Síntomas Afectivos/epidemiología , Femenino , Humanos , Masculino , Prevalencia
3.
Artículo en Inglés | MEDLINE | ID: mdl-37586980

RESUMEN

INTRODUCTION: A reduced platelet count (PLT) is a frequent post-operative finding in orthopedic surgery patients. Despite its prevalence, the characteristics of post-surgical thrombocytopenia have not been well described. METHODS: A retrospective chart review was conducted on patients who underwent a knee or hip replacement from 2012 to 2015. Patients who received heparin were excluded. RESULTS: A total of 56 patients were analyzed on post-operative days 0 to 4. By day 1, 90.9% of the patients experienced a reduction in their platelet counts. The lowest mean platelet count (nadir) occurred on day 2 (201.3 × 109/L). The average decrease in the platelet count from the baseline was 24% (95%CI: 20.6 - 27.2). The change in the platelet count from the baseline ranged from a 49.6% drop to a 14.2% increase. A substantial portion of patients experienced thrombocytopenia, with 28% occurring on day 2. Platelet counts less than 100 × 109/L occurred only once. The percent decrease in the platelet count from the baseline to any other time point was significantly larger in patients aged > 65 years, compared to patients aged ≤ 65 years (p = 0.007). Specifically, the average drop in the platelet count at the nadir (day 2) relative to the baseline was 27.8% in patients aged > 65 years, compared to 19.5% in patients aged ≤ 65 years. CONCLUSIONS: A reduction in the platelet count is a frequent post-operative finding in orthopedic surgery patients, even after removing confounding factors, such as heparin exposure, but clinical thrombocytopenia is uncommon. Alternative etiologies should be considered when the platelet count is less than 100 × 109/L. Vigilance should also be considered regarding elderly patients.

4.
IDCases ; 31: e01659, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36589767

RESUMEN

Richter Transformation (RT) is the phenomenon of progression from Chronic Lymphocytic Leukemia (CLL) into an aggressive Large-Cell Lymphoma and is typically characterized by diffuse lymphadenopathy combined with the classical "B symptoms". While rare, other causes of sudden onset diffuse lymphadenopathy in patients with CLL can occur; one of the rarest being necrotic herpes simplex lymphadenitis. We report a case that presented similarly to Richter Transformation including PET-CT scan findings consistent with RT but was histologically proven to be necrotic herpes simplex lymphadenitis. We identified less than 20 reported cases of this phenomenon in English language literature. Our patient was successfully treated with appropriate antiviral therapy due to timely recognition of the correct disease process. Our case reinforces the importance of maintaining diagnostic suspicion when approaching sudden onset lymphadenitis in this patient population.

5.
N Z Med J ; 126(1370): 110-2, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23474519

RESUMEN

Oral direct thrombin inhibitors have improved treatment of non-valvular atrial fibrillation. Safety concerns have been raised since there is no antidote for treatment of secondary haemorrhages and the absence of widely validated test to monitor drug levels. We present a case of dabigatran overdose in an 82-year-old female who was treated with a seemingly appropriate dose.


Asunto(s)
Lesión Renal Aguda/complicaciones , Antitrombinas/efectos adversos , Antitrombinas/farmacocinética , Bencimidazoles/efectos adversos , Bencimidazoles/farmacocinética , Sobredosis de Droga , beta-Alanina/análogos & derivados , Anciano de 80 o más Años , Amiodarona/uso terapéutico , Antiarrítmicos/uso terapéutico , Antitrombinas/administración & dosificación , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/administración & dosificación , Creatinina/análisis , Dabigatrán , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Fibrinógeno/análisis , Humanos , Tiempo de Trombina , beta-Alanina/administración & dosificación , beta-Alanina/efectos adversos , beta-Alanina/farmacocinética
6.
J Thorac Cardiovasc Surg ; 143(5): 1198-204, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22285329

RESUMEN

OBJECTIVE: Postoperative bleeding is a major cause of morbidity and mortality after complex aortic surgery. Intraoperative coagulopathy is a well-known culprit in this process. Recombinant activated factor VII is increasingly used for the postoperative management of such bleeding. We report our experience with the intraoperative use of this agent. METHODS: We performed a propensity-matched analysis on 376 retrospectively identified patients who underwent aortic root, arch, or ascending aortic replacement surgeries from 1999 to 2010. We matched a total of 58 patients: recombinant activated factor VII-treated group (n = 29) and nonrecombinant activated factor VII-treated group (n = 29). We compared the matched patients on re-exploration, mortality, bleeding-related events, use of blood and blood products, length of intensive care unit stay, duration of hospitalization, and thrombotic complications. RESULTS: Propensity-matched patients had similar preoperative and intraoperative characteristics. The mean dose of recombinant activated factor VII group was 23 ± 12 µg/kg. We found significantly lower rates of surgical re-exploration (P = .004), fewer prolonged intubations (P = .004), less total chest tube output (P = .01), and fewer units of packed red blood cells (P = .01) and fresh-frozen plasma (P = .04) transfused postoperatively in the recombinant activated factor VII group. There was no significant difference in mortality (P = 1), duration of intensive care unit stay (P = .44) or hospital stay (P = .32), or thrombotic complications between the groups (P = .5). CONCLUSIONS: We recommend the intraoperative administration of low-dose recombinant activated factor VII but limited to the management of persistent, nonsurgical, mediastinal bleeding in aortic surgery. Further prospective randomized studies and larger cohorts are needed to verify these findings.


Asunto(s)
Aneurisma de la Aorta/cirugía , Implantación de Prótesis Vascular/efectos adversos , Factor VIIa/administración & dosificación , Hemostáticos/administración & dosificación , Hemorragia Posoperatoria/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Aneurisma de la Aorta/mortalidad , Transfusión Sanguínea , Implantación de Prótesis Vascular/mortalidad , Esquema de Medicación , Factor VIIa/efectos adversos , Femenino , Hemostáticos/efectos adversos , Humanos , Unidades de Cuidados Intensivos , Cuidados Intraoperatorios , Tiempo de Internación , Modelos Logísticos , Masculino , Persona de Mediana Edad , Ciudad de Nueva York , Hemorragia Posoperatoria/etiología , Hemorragia Posoperatoria/mortalidad , Puntaje de Propensión , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Sistema de Registros , Reoperación , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Trombosis/etiología , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
7.
Spine (Phila Pa 1976) ; 28(12): E221-3, 2003 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-12811284

RESUMEN

STUDY DESIGN: A report of two cases is presented. OBJECTIVE: To raise awareness of bovine thrombin-induced factor V deficiency. SUMMARY OF BACKGROUND DATA: Bovine thrombin is a frequently used hemostatic agent in spinal surgery. Current preparations contain clotting factors in addition to thrombin, particularly factor V, which are immunogenic. Re-exposure of sensitized patients to bovine thrombin products during subsequent surgery may lead to the formation of antibodies that cross-react with human clotting factors, most commonly against factor V. Hemorrhagic complications have been reported in nonspinal patients due to a bovine thrombin-induced factor V deficiency. METHODS: Two spinal cases are reported, and the literature is reviewed. RESULTS: In the cases outlined, both patients underwent revision spinal surgery, with re-exposure to bovine thrombin. Both patients developed abnormal coagulation profiles, with an acquired factor V deficiency. No hemorrhagic complications occurred; however, second-stage surgery was delayed in one patient and not undertaken in the other. In both patients, the coagulopathy resolved spontaneously. CONCLUSIONS: Bovine thrombin-induced coagulopathy is well recognized in cardiac surgery but has not been reported in spinal surgical patients. Data available from cardiac surgical patients suggests that those who are sensitized to two or more bovine clotting factors are at greatest risk of hemorrhagic complications. The cases we present demonstrate that this phenomenon occurs in spinal surgical patients and serve to raise awareness of the potential danger of bovine thrombin in sensitized patients.


Asunto(s)
Deficiencia del Factor V/inducido químicamente , Factor V/antagonistas & inhibidores , Cifosis/inmunología , Estenosis Espinal/inmunología , Trombina/efectos adversos , Factor V/inmunología , Deficiencia del Factor V/inmunología , Femenino , Humanos , Cifosis/cirugía , Masculino , Persona de Mediana Edad , Dispositivos de Fijación Ortopédica , Tiempo de Protrombina , Reoperación , Fusión Vertebral , Estenosis Espinal/cirugía , Trombina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA